Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NextEra Energy, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while NextEra Energy, Inc. trades at $85.65 (market cap $178.85B). The key difference: NextEra Energy, Inc. is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and NextEra Energy, Inc. pays a 2.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NEE | |
|---|---|---|
Market Cap | $29.60B | $178.85B |
Sector | Health | Utilities |
52-Week High | $491.22 | $97.88 |
52-Week Low | $205.48 | $69.77 |
Enterprise Value | $27.56B | $286.18B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NextEra Energy (NEE) trades at $84.70, showing minimal daily movement. The stock exhibits a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. Financially, the company maintains strong profitability with a 32.4% net income margin and benefits from growing electricity demand driven by AI data center expansion, as highlighted in recent partnerships like the $100 billion Kentucky data center project with Brookfield (The Motley Fool, 2026-07-29).
Outlook remains positive due to robust dividend payments and strategic positioning in AI power infrastructure, though risks include high capital expenditures and rising debt levels. Analyst consensus is bullish with a $100.40 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
